The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Among inpatients at an academic center, serial adjunctive ketamine infusions were no more effective at treating major depression than midazolam, according to a randomized clinical trial published in ...

Johnson & Johnson (JNJ) stock is in focus as the FDA further expands the labeling for its antipsychotic to treat adults with ...

Researchers determined the effect of prenatal and early postnatal lead exposure on risk for depression and anxiety in adulthood.

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...